

ASX RELEASE

6 February 2020

Board Restructuring

Amplia Therapeutics Limited (“Amplia”, the “Company”), announces a significant restructuring of the Board of Directors of the Company. The following Directors have today retired from the Board of the Company:

- Dr. Christian Behrenbruch (Non-Executive Director)
- Mr. Simon Wilkinson (Non-Executive Director)
- Mr. Andrew Cooke (Non-Executive Director)

Mr. Cooke will remain engaged by the Company as the Company Secretary.

With the completion of recent capital raising activity (ASX releases dated 12 June 2019 and 20 January 2020) and the approaching anniversary of the completion of the Amplia asset purchase, the Company believes that it is a good time to implement the outcome of a governance and management structure review which commenced with the successful appointment of Dr. John Lambert as CEO (ASX release dated 24 June 2019).

Amplia Chairman Dr. Warwick Tong stated, “With the completion of the Amplia transaction, management transition and capital raise we feel it is an ideal time to streamline the Board. This simplification of the Board structure, befitting of a small-cap biotechnology company, will enable Amplia to remain a nimble decision-making entity as it navigates the clinical translation of its oncology assets and commercial partnerships over the next 12 months. The reduced size of the Amplia Board also opens the opportunity for the near-term hiring of an additional Non-Executive Director to potentially begin to address the Company’s lack of diversity in the boardroom.”

Amplia Co-Founder Dr. Christian Behrenbruch stated, “I’d like to personally thank Andrew and Simon for their leadership and commitment to the restructuring of the Company following the acquisition of Amplia Therapeutics. Re-engineering a biotechnology company on the back-end of clinical failure is a challenging and thankless task that requires a unique combination of business nous, integrity and tenacity.”

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics Limited.

For Further Information

Dr. John Lambert
Chief Executive Officer
john@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).